Literature DB >> 31343218

Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis.

Zoe Moon1, Rona Moss-Morris1, Myra S Hunter1, Sam Norton1, Lyndsay D Hughes1.   

Abstract

OBJECTIVE: Previous research has shown that up to 50% of breast cancer survivors prescribed tamoxifen do not take it as recommended, which is associated with increased risk of recurrence and mortality. Little research has attempted to identify modifiable psychosocial factors associated with tamoxifen nonadherence. This study aimed to examine how tamoxifen adherence rates change over a year and to identify modifiable predictors of nonadherence.
METHOD: Three hundred and forty-five breast cancer survivors who were in their first year of tamoxifen prescription were sent questionnaires at 4 points over a 12-month period. Questionnaires assessed demographic and clinical factors, side effects, beliefs about the illness and medication, social support, distress and tamoxifen adherence. Adherence was assessed using the Medication Adherence Rating Scale. Latent Growth Modeling was used to identify predictors of tamoxifen nonadherence.
RESULTS: Reported rates of nonadherence increased over time (37-48%). Several demographic, clinical, and psychosocial variables were associated with nonadherence. Women who were nonadherent were more likely to be from a minority ethnic group, to have more negative medication beliefs and to have lower confidence in their ability to take tamoxifen.
CONCLUSIONS: These demographic and clinical variables can be used to identify women at higher risk of nonadherence. The modifiable psychosocial variables can be used as the basis for psychological interventions to improve adherence in this population. Interventions should focus on both intentional and unintentional nonadherence. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31343218     DOI: 10.1037/hea0000785

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  7 in total

Review 1.  Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.

Authors:  Lamya Alnaim
Journal:  Eur J Breast Health       Date:  2022-10-01

2.  Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients.

Authors:  Niklas Gremke; Sebastian Griewing; Saket Chaudhari; Swati Upadhyaya; Ivan Nikolov; Karel Kostev; Matthias Kalder
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-23       Impact factor: 4.322

Review 3.  The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.

Authors:  Leanne Fleming; Sommer Agnew; Nicola Peddie; Megan Crawford; Diane Dixon; Iain MacPherson
Journal:  Breast       Date:  2022-05-14       Impact factor: 4.254

4.  Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study.

Authors:  Sumi Sung; Yul Ha Min; Seul Ki Park; Sae Byul Lee
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

5.  Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.

Authors:  Sophie M C Green; David P French; Christopher D Graham; Louise H Hall; Nikki Rousseau; Robbie Foy; Jane Clark; Catherine Parbutt; Erin Raine; Benjamin Gardner; Galina Velikova; Sally J L Moore; Jacqueline Buxton; Samuel G Smith
Journal:  BMC Health Serv Res       Date:  2022-08-24       Impact factor: 2.908

6.  Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework.

Authors:  Zoe Moon; Rona Moss-Morris; Myra S Hunter; Lyndsay D Hughes
Journal:  Support Care Cancer       Date:  2020-10-29       Impact factor: 3.603

Review 7.  Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.

Authors:  Neil Carleton; Azadeh Nasrazadani; Kristine Gade; Sushil Beriwal; Parul N Barry; Adam M Brufsky; Rohit Bhargava; Wendie A Berg; Margarita L Zuley; G J van Londen; Oscar C Marroquin; Darcy L Thull; Phuong L Mai; Emilia J Diego; Michael T Lotze; Steffi Oesterreich; Priscilla F McAuliffe; Adrian V Lee
Journal:  Lancet Healthy Longev       Date:  2022-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.